Jori A L Wagenaars
Overview
Explore the profile of Jori A L Wagenaars including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
402
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liemburg-Apers D, Wagenaars J, Smeitink J, Willems P, Koopman W
J Cell Sci
. 2016 Nov;
129(23):4411-4423.
PMID: 27793977
Mitochondria play a central role in cellular energy production, and their dysfunction can trigger a compensatory increase in glycolytic flux to sustain cellular ATP levels. Here, we studied the mechanism...
2.
Cheng S, Scicluna B, Arts R, Gresnigt M, Lachmandas E, Giamarellos-Bourboulis E, et al.
Nat Immunol
. 2016 Mar;
17(4):406-13.
PMID: 26950237
The acute phase of sepsis is characterized by a strong inflammatory reaction. At later stages in some patients, immunoparalysis may be encountered, which is associated with a poor outcome. By...
3.
Grefte S, Wagenaars J, Jansen R, Willems P, Koopman W
Biochim Biophys Acta
. 2015 Apr;
1853(7):1606-14.
PMID: 25827955
Rotenone (ROT) is a widely used inhibitor of complex I (CI), the first complex of the mitochondrial oxidative phosphorylation (OXPHOS) system. However, particularly at high concentrations ROT was also described...
4.
Zeelenberg I, van Maren W, Boissonnas A, van Hout-Kuijer M, Den Brok M, Wagenaars J, et al.
J Immunol
. 2011 Jun;
187(3):1281-8.
PMID: 21705625
Effective antitumor immunotherapy requires the identification of suitable target Ags. Interestingly, many of the tumor Ags used in clinical trials are present in preparations of secreted tumor vesicles (exosomes). In...
5.
Nierkens S, den Brok M, Roelofsen T, Wagenaars J, Figdor C, Ruers T, et al.
PLoS One
. 2009 Dec;
4(12):e8368.
PMID: 20020049
Background: The TLR9 agonist CpG is increasingly applied in preclinical and clinical studies as a therapeutic modality to enhance tumor immunity. The clinical application of CpG appears, however, less successful...